With aureosan®, we have found an active ingredient in the lactic acid bacterium Lactobacillus gasseri DSM25908 that effectively and precisely binds Staphylococcus aureus, including resistant strains (MRSA), and removes it from the skin and mucosal lesions. aureosan® is suitable for the treatment of chronic wounds as well as for the cleansing of skin areas colonised by S. aureus, such as those found in atopic dermatitis and acne skin.
aureosan® also provides a solution for increasingly urgent hygiene requirements in hospitals, clinics and care facilities, when multi-resistant germs in patients, nursing staff and visitors need to be removed non-antibiotically.
aureosan® is currently in the clinical trial stage. The active ingredient aureosan® is protected by patent.